Recombinant Human XAGE2 Protein，GST

XAGE2, a member of the cancer/testis (CT) antigen family, has garnered increasing interest in cancer research due to its restricted expression in normal tissues and prominent upregulation in various malignancies. As an immune target, XAGE2 is primarily expressed in germ cells of the testis, making it an ideal candidate for cancer immunotherapy, particularly in tumors where it is overexpressed, such as melanoma and certain types of lung cancer. Research has shown that XAGE2 can elicit T cell responses, suggesting its potential as a target for therapeutic vaccines. Furthermore, studies indicate that the presence of antibodies against XAGE2 correlates with improved patient prognosis, highlighting its relevance in tumor immunology. Investigating the recombinant protein forms of XAGE2 may provide valuable insights into its structural and functional characteristics, facilitating the development of novel immunotherapeutic strategies. This includes the generation of XAGE2-based vaccines and engineered T cell therapies, aiming to harness the immune system to specifically target cancer cells expressing this antigen. The exploration of XAGE2 recombinant proteins not only enhances our understanding of tumor immunity but also paves the way for personalized medicine approaches in oncology, where targeting CT antigens becomes a crucial strategy in developing effective cancer treatments. As research continues to unveil the complexities of the tumor microenvironment and immune interactions, XAGE2 stands out as a promising focal point for advancing cancer immunotherapy.